Category: eLife

“All very painful:” Two retractions to watch for, in eLife and PLOS ONE

We have news of two upcoming retractions, both following critiques on PubPeer.

PLOS ONE is retracting a 2012 paper by researchers at the Istituto Superiore di Sanità in Rome and the World Health Organization’s International Agency for Research on Cancer in Lyon, France, “Interferon-β Induces Cellular Senescence in Cutaneous Human Papilloma Virus-Transformed Human Keratinocytes by Affecting p53 Transactivating Activity.”

PubPeer commenters first left critiques of the paper on August 6 of last year, noting likely splicing and other manipulation of images. Several days later, pseudonymous whistleblower Claire Francis contacted the journal to flag similar issues. On Wednesday of this week, a journal representative emailed Francis to say the paper would be retracted: Continue reading “All very painful:” Two retractions to watch for, in eLife and PLOS ONE

Research problems at Australian university hit the news

A university in Australia that’s made headlines before over allegations of research misconduct has found itself in the news once again.

Last week, the University of Queensland (UQ) announced some of its authors were retracting a paper after discovering data were missing. Just days later, the university made headlines over an investigation into three papers about controversial therapies that were OK’d by UQ ethics committees. Continue reading Research problems at Australian university hit the news

At last, cancer reproducibility project releases some results — and they’re mixed

Nearly five years ago, researchers suggested that the vast majority of preclinical cancer research wouldn’t hold up to follow-up experiments, delaying much needed treatments for patients. In a series of articles publishing tomorrow morning, eLife has released the results of the first five attempts to replicate experiments in cancer biology — and the results are decidedly mixed.

As our co-founders Adam Marcus and Ivan Oransky write in STAT, the overall take-home message was that two studies generated findings similar to the original, one did not replicate the original, and two others were inconclusive.

They quote Brian Nosek, a psychologist at the University of Virginia, in Charlottesville, who runs the Center for Open Science, who has been leading the replication effort in his own field:

Continue reading At last, cancer reproducibility project releases some results — and they’re mixed

Structural biology corrections highlight best of the scientific process

Nature_latest-coverIf you need evidence of the value of transparency in science, check out a pair of recent corrections in the structural biology literature.

This past August, researchers led by Qiu-Xing Jiang at the University of Texas Southwestern Medical Center corrected their study, first published in February 2014 in eLife, of prion-like protein aggregates called MAVS filaments, to which they had ascribed the incorrect “helical symmetry.” In March, Richard Blumberg of Harvard Medical School, and colleagues corrected their 2014 Nature study of a protein complex called CEACAM1/TIM-3, whose structure they had attempted to solve using x-ray crystallography.

In both cases, external researchers were able to download and reanalyze the authors’ own data from public data repositories, making it quickly apparent what had gone wrong and how it needed to be fixed — highlighting the very best of a scientific process that is supposed to be self-correcting and collaborative. Continue reading Structural biology corrections highlight best of the scientific process

Much of preclinical research into one cancer drug is flawed, says report

elife-identity-headerA review of preclinical research of a now widely used cancer drug suggests the studies contain multiple methodology flaws and overestimate the benefits of the drug.

Specifically, the researchers found that most studies didn’t randomize treatments, didn’t blind investigators to which animals were receiving the drug, and tested tumors in only one animal model, which limits the applicability of the results. Importantly, they also found evidence that publication bias — keeping studies that found no evidence of benefit from the drug, sunitinib, out of the literature — may have caused a significant overestimation of its effects on various tumor types.

Together, these findings suggest the need for a set of standards that cancer researchers follow, the journal notes in a “digest” of the paper, published Tuesday by eLife:
Continue reading Much of preclinical research into one cancer drug is flawed, says report